Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 5
2009 2
2010 3
2011 1
2012 2
2013 2
2014 6
2018 1
2019 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Results by year
Filters applied: . Clear all
Page 1
Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.
Joudeh J, Claxton D. Joudeh J, et al. Expert Opin Investig Drugs. 2012 Mar;21(3):363-73. doi: 10.1517/13543784.2012.652302. Epub 2012 Feb 11. Expert Opin Investig Drugs. 2012. PMID: 22324354 Review.
AREAS COVERED: The pan Bcl-2 family member BH3 domain mimetic obatoclax (GX15-070) is currently under clinical evaluation in solid tumors and hematological neoplasms. ...Pharmacology, pharmacodynamics, drug resistance and clinical use of this agent in leukemias and lymphom …
AREAS COVERED: The pan Bcl-2 family member BH3 domain mimetic obatoclax (GX15-070) is currently under clinical evaluation in solid tu …
Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling.
Chen S, Ren Y, Duan P. Chen S, et al. Biomed Pharmacother. 2020 Sep;129:110371. doi: 10.1016/j.biopha.2020.110371. Epub 2020 Jun 18. Biomed Pharmacother. 2020. PMID: 32563984 Free article.
Lung cancer still remains a leading cause of cancer mortality in the world. Obatoclax mesylate (OM), a B cell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) family antagonist, is a potential antitumor drug. ...Although these inherent defects, nanotechnology can be …
Lung cancer still remains a leading cause of cancer mortality in the world. Obatoclax mesylate (OM), a B cell chronic lymphocy …
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.
Chiappori A, Williams C, Northfelt DW, Adams JW, Malik S, Edelman MJ, Rosen P, Van Echo DA, Berger MS, Haura EB. Chiappori A, et al. J Thorac Oncol. 2014 Jan;9(1):121-5. doi: 10.1097/JTO.0000000000000027. J Thorac Oncol. 2014. PMID: 24346101 Free PMC article. Clinical Trial.
INTRODUCTION: The proapoptotic small-molecule pan-Bcl-2 inhibitor obatoclax mesylate (GX15-070) may enhance the cytotoxicity of chemotherapy in relapsed/refractory non-small-cell lung cancer (NSCLC). ...Neutropenia (31%), febrile neutropenia (16%), and dyspnea (19%) …
INTRODUCTION: The proapoptotic small-molecule pan-Bcl-2 inhibitor obatoclax mesylate (GX15-070) may enhance the cytotoxicity o …
An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies.
Goard CA, Schimmer AD. Goard CA, et al. Core Evid. 2013;8:15-26. doi: 10.2147/CE.S42568. Epub 2013 Mar 14. Core Evid. 2013. PMID: 23515850 Free PMC article.
Obatoclax mesylate is an intravenously-administered drug under investigation in Phase I and II clinical trials as a novel anticancer therapeutic for hematological malignancies and solid tumors. ...By understanding the molecular underpinnings of obatoclax resp
Obatoclax mesylate is an intravenously-administered drug under investigation in Phase I and II clinical trials as a novel anti
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM. Paik PK, et al. Cancer Chemother Pharmacol. 2010 Nov;66(6):1079-85. doi: 10.1007/s00280-010-1265-5. Epub 2010 Feb 18. Cancer Chemother Pharmacol. 2010. PMID: 20165849 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Patients with solid tumor malignancies for whom topotecan was an appropriate treatment were administered obatoclax mesylate and topotecan on a 3-week cycle in a pre-defined, standard 3 + 3 dose escalation scheme. The starting dose for obatoc
PATIENTS AND METHODS: Patients with solid tumor malignancies for whom topotecan was an appropriate treatment were administered obatoclax
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM. Paik PK, et al. Lung Cancer. 2011 Dec;74(3):481-5. doi: 10.1016/j.lungcan.2011.05.005. Epub 2011 May 26. Lung Cancer. 2011. PMID: 21620511 Free PMC article. Clinical Trial.
INTRODUCTION: We previously reported data on the safety, tolerability, and recommended phase II dose of obatoclax mesylate in conjunction with topotecan in patients with advanced solid tumor malignancies. ...METHODS: This was an open-label, single-arm, phase II exte …
INTRODUCTION: We previously reported data on the safety, tolerability, and recommended phase II dose of obatoclax mesylate in …
A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.
Schimmer AD, Raza A, Carter TH, Claxton D, Erba H, DeAngelo DJ, Tallman MS, Goard C, Borthakur G. Schimmer AD, et al. PLoS One. 2014 Oct 6;9(10):e108694. doi: 10.1371/journal.pone.0108694. eCollection 2014. PLoS One. 2014. PMID: 25285531 Free PMC article. Clinical Trial.
EXPERIMENTAL DESIGN: Phase I evaluated the safety of obatoclax infused for 3 hours on 3 consecutive days (3 h 3 d) in 2-week cycles. Initial obatoclax dose was 30 mg/day (3 h 3 d; n = 3). Obatoclax was increased to 45 mg/day (3 h 3 d) if 1 patient had a dose- …
EXPERIMENTAL DESIGN: Phase I evaluated the safety of obatoclax infused for 3 hours on 3 consecutive days (3 h 3 d) in 2-week cycles. …
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.
O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. O'Brien SM, et al. Blood. 2009 Jan 8;113(2):299-305. doi: 10.1182/blood-2008-02-137943. Epub 2008 Oct 17. Blood. 2009. PMID: 18931344 Free PMC article. Clinical Trial.
Obatoclax mesylate is a small molecule pan-Bcl-2 antagonist with in vitro activity against chronic lymphocytic leukemia (CLL) cells. ...Obatoclax mesylate has biologic activity and modest single-agent activity in heavily pretreated patients with advanc
Obatoclax mesylate is a small molecule pan-Bcl-2 antagonist with in vitro activity against chronic lymphocytic leukemia (CLL)
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.
Goy A, Hernandez-Ilzaliturri FJ, Kahl B, Ford P, Protomastro E, Berger M. Goy A, et al. Leuk Lymphoma. 2014 Dec;55(12):2761-8. doi: 10.3109/10428194.2014.907891. Epub 2014 May 6. Leuk Lymphoma. 2014. PMID: 24679008 Free PMC article. Clinical Trial.
This phase I/II study assessed obatoclax plus bortezomib in patients with relapsed/refractory MCL. ...In phase I, the combination was feasible at all doses. Obatoclax 45 mg plus bortezomib 1.3 mg/m(2) was selected for phase II study. ...
This phase I/II study assessed obatoclax plus bortezomib in patients with relapsed/refractory MCL. ...In phase I, the combination was …
24 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page